Patent lawsuit filed against BioNTech about Covid-19 vaccine

A patent infringement lawsuit was filed against BioNTech, which produces the world’s first Covid-19 vaccine using mRNA technology. CureVac, one of Germany’s leading biotechnology companies, claimed “fair compensation” for allegedly violating CureVac’s patents in the mRNA technology used by BioNTech.

Covid-19 vaccine sales and production will continue uninterrupted

In the statement made by CureVac; Emphasizing that Curevac has been working on mRNA technology for more than 20 years, it was stated that BioNTech and its two subsidiaries were seeking fair compensation for intellectual property violations. CureVac stated that it did not request injunctive relief. He stated that BioNTech does not intend to take legal action to prevent the production, sale or distribution of Covid-19 vaccines.

Statement from BioNTech: “We will defend strongly”

Founded by Uğur Şahin and Özlem Türeci, BioNTech has released an official statement about CureVac’s claims. In the statement, it was announced that all intellectual property rights are valued and respected, but BioNTech will defend strongly against all patent infringement claims about the Covid-19 vaccine.

Noting the success of BioNTech’s Covid-19 vaccine, the statement said, “BioNTech’s vaccine work is original and we will vigorously defend it against all claims of patent infringement.” statement was included.

BioNTech, which is the leader in Covid-19 vaccine sales together with its production cooperation with Pfizer, has become one of the fastest growing companies in 2020 and 2021. The company generated revenues of €19 billion from vaccines last year. This year’s revenue is expected to be 17 billion euros.